News

Under the terms of the partnership, South Korea-based Celltrion will undertake manufacturing and supply of four recombinant antibodies to iProgen. Among the four antibodies, two will be targeting

INFUGEM, the first chemotherapy product that comes in a premixed, ready-to-infuse formulation, was approved by the U.S. Food and Drug Administration (FDA) in July 2018 in combination with

The material collaboration terms for patisiran, vutrisiran, and fitusiran, as previously announced, will continue unchanged. “Our landmark 2014 rare disease alliance with Sanofi resulted in the advancement of

The company has submitted a supplemental new drug application (sNDA) to the FDA for Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets) for PrEP to reduce

The US Department of Justice (DOJ) alleged that the three pharmaceutical firms have violated the False Claims Act by illegally paying the Medicare or Civilian Health and Medical

The cohorts that have been expanded are (i) HER2 mutant patients with metastatic salivary gland cancer and (ii) patients with EGFR exon 18 mutation-positive lung cancer. The Phase

Under the terms of the agreement, LakePharma will have the ability to offer Twist’s proprietary antibody discovery and optimization platforms to their existing and future biopharmaceutical customers as

The approval was based on data from Archer 1050 randomized, multicenter, multinational and open-label phase 3 study conducted in patients with unresectable, metastatic or recurrent NSCLC harboring EGFR

Pegfilgrastim is a long-acting version of filgrastim and may be prescribed to appropriate cancer patients undergoing chemotherapy to enhance the production of infection-fighting white blood cells2. Studies have